Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bilgin

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Science (New York, N.Y.)|July 28, 2001
Global analysis of protein activities using proteome chipsH Zhu, M Bilgin, R Bangham, et al.
Transfusion|February 3, 2015
Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factorYavuz M Bilgin, Otto Visser, Erik A M Beckers, et al.
Blood|June 30, 2023
Risk of male breast cancer after Hodgkin lymphomaSimone de Vries, Inge M Krul, Michael Schaapveld, et al.
BMC Women'S Health|April 5, 2019
Cyprus Women's Health Research (COHERE) initiative: determining the relative burden of women's health conditions and related co-morbidities in an Eastern Mediterranean populationM B Hocaoglu, S Gurkas, T Karaderi, et al.
Blood Cancer Journal|May 22, 2023
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patientsA Vera de Jonge, Erik van Werkhoven, Avinash G Dinmohamed, et al.
British Journal of Haematology|July 11, 2019
Rituximab-PECC induction followed by <sup>90</sup> Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON studyPieternella J Lugtenburg, Josee M Zijlstra, Jeanette K Doorduijn, et al.
Haematologica|July 4, 2024
Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphomaA Vera De Jonge, Wassilis S C Bruins, Carolien Duetz, et al.
British Journal of Haematology|May 16, 2019
Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphomaAnnelies Nijdam, Nicky Dekker, Berthe M P Aleman, et al.
Blood|November 22, 2024
Beyond static measurements: dynamic frailty improves survival prediction in multiple myelomaFebe Smits, Kaz Groen, Mark-David Levin, et al.
Journal of the National Cancer Institute|April 6, 2026
Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patientsShahin Roshani, Naomi B Boekel, Flora E Van Leeuwen, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Science (New York, N.Y.)|July 28, 2001
Global analysis of protein activities using proteome chipsH Zhu, M Bilgin, R Bangham, et al.
Transfusion|February 3, 2015
Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factorYavuz M Bilgin, Otto Visser, Erik A M Beckers, et al.
Blood|June 30, 2023
Risk of male breast cancer after Hodgkin lymphomaSimone de Vries, Inge M Krul, Michael Schaapveld, et al.
BMC Women'S Health|April 5, 2019
Cyprus Women's Health Research (COHERE) initiative: determining the relative burden of women's health conditions and related co-morbidities in an Eastern Mediterranean populationM B Hocaoglu, S Gurkas, T Karaderi, et al.
Blood Cancer Journal|May 22, 2023
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patientsA Vera de Jonge, Erik van Werkhoven, Avinash G Dinmohamed, et al.
British Journal of Haematology|July 11, 2019
Rituximab-PECC induction followed by <sup>90</sup> Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON studyPieternella J Lugtenburg, Josee M Zijlstra, Jeanette K Doorduijn, et al.
Haematologica|July 4, 2024
Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphomaA Vera De Jonge, Wassilis S C Bruins, Carolien Duetz, et al.
British Journal of Haematology|May 16, 2019
Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphomaAnnelies Nijdam, Nicky Dekker, Berthe M P Aleman, et al.
Blood|November 22, 2024
Beyond static measurements: dynamic frailty improves survival prediction in multiple myelomaFebe Smits, Kaz Groen, Mark-David Levin, et al.
Journal of the National Cancer Institute|April 6, 2026
Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patientsShahin Roshani, Naomi B Boekel, Flora E Van Leeuwen, et al.
Pageof 8